Quantifying disease progression in amyotrophic lateral sclerosis

Annals of Neurology

Volumn 76, Issue 5, 2014, Pages 643-657

  Simon, Neil G ^a,b,c   Turner, Martin R ^d   Vucic, Steve ^c,e   Al Chalabi, Ammar ^f   Shefner, Jeremy ^g   Lomen Hoerth, Catherine ^a   Kiernan, Matthew C ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e University of Sydney   (Australia)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^h UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

AMYOTROPHIC LATERAL SCLEROSIS; DISEASE COURSE; ELECTRODIAGNOSIS; FUNCTIONAL ASSESSMENT; HEREDITY; HUMAN; MOTOR UNIT; MUSCLE STRENGTH; NEUROIMAGING; PHENOTYPE; REVIEW; SURVIVAL; TRANSCRANIAL MAGNETIC STIMULATION; BRAIN; GENETICS; PATHOLOGY; PATHOPHYSIOLOGY; PSYCHOLOGY; SKELETAL MUSCLE; SPINAL CORD;

AMYOTROPHIC LATERAL SCLEROSIS; BRAIN; DISEASE PROGRESSION; HUMANS; MUSCLE, SKELETAL; SPINAL CORD;

EID: 84912532654     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24273     Document Type: Review

References (120)

1. Ravits J, Paul P, Jorg C. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 2007;68: 1571-1575.
2. Fujimura-Kiyono C, Kimura F, Ishida S, et al. Onset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011;82:1244-1249.
3. Sekiguchi T, Kanouchi T, Shibuya K, et al. Spreading of amyotrophic lateral sclerosis lesions-multifocal hits and local propagation? J Neurol Neurosurg Psychiatry 2014;85:85-91.
4. Simon NG, Lomen-Hoerth C, Kiernan MC. Patterns of clinical and electrodiagnostic abnormalities in early amyotrophic lateral sclerosis. Muscle Nerve 2014 Mar 20. doi: 10.1002/mus.24244.
5. Roche JC, Rojas-Garcia R, Scott KM, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain 2012;135: 847-852.
6. Balendra R, Jones A, Jivraj N, et al. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J Neurol Neurosurg Psychiatry 2014 Jan 24. doi: 10.1136/jnnp-2013-306865.
7. Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013;9:617-628.
8. Talbot K. Motor neuron disease: the bare essentials. Pract Neurol 2009;9:303-309.
9. Vucic S, Kiernan MC. Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2007;78:849-852.
10. Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology 2006;66:647-653.
11. Rosenfeld J, Swash M. What's in a name? Lumping or splitting ALS, PLS, PMA, and the other motor neuron diseases. Neurology 2006;66:624-625.
12. Abel O, Powell JF, Andersen PM, Al-Chalabi A. ALSoD: a userfriendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum Mutat 2012;33:1345-1351.
13. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol 2011;7: 603-615.
14. Byrne S, Elamin M, Bede P, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol 2012;11:232-240.
15. Elamin M, Bede P, Byrne S, et al. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology 2013;80:1590-1597.
16. Su XW, Broach JR, Connor JR, et al. Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research. Muscle Nerve 2014;49:786-803.
17. Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014;17:17-23.
18. Prize4Life and Neurological Clinical Research Institute MGH. Pooled Resource Open-Access ALS Clinical Trials database. 2014. Available at: https://nctu.partners.org/ProACT. Accessed July 22, 2014.
19. Williams KL, Fifita JA, Vucic S, et al. Pathophysiological insights into ALS with C9ORF72 expansions. J Neurol Neurosurg Psychiatry 2013;84:931-935.
20. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (phase III). J Neurol Sci 1999;169:13-21.
21. Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRSR at time of diagnosis predicts survival time in ALS. Neurology 2006;66:265-267.
22. Franchignoni F, Mora G, Giordano A, et al. Evidence of multidimensionality in the ALSFRS-R scale: a critical appraisal on its measurement properties using Rasch analysis. J Neurol Neurosurg Psychiatry 2013;84:1340-1345.
23. Berry JD, Cudkowicz ME. New considerations in the design of clinical trials for amyotrophic lateral sclerosis. Clin Invest 2011;1: 1375-1389.
24. Berry JD, Miller R, Moore DH, et al. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener 2013;14: 162-168.
25. Medical Research Council. Aid to the examination of the peripheral nervous system. London, UK: Her Majesty's Stationary Office, 1976.
26. Goonetilleke A, Modarres-Sadeghi H, Guiloff RJ. Accuracy, reproducibility, and variability of hand-held dynamometry in motor neuron disease. J Neurol Neurosurg Psychiatry 1994;57:326-332.
27. Andres PL, Hedlund W, Finison L, et al. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 1986;36: 937-941.
28. Great Lakes ALS Study Group. A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. Neurology 2003;61:1503-1507.
29. Andres PL, Skerry LM, Thornell B, et al. A comparison of three measures of disease progression in ALS. J Neurol Sci 1996; 139(suppl):64-70.
30. Whittaker RG, Ferenczi E, Hilton-Jones D. Myotonic dystrophy: practical issues relating to assessment of strength. J Neurol Neurosurg Psychiatry 2006;77:1282-1283.
31. Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry 2006;77:390-392.
32. Baumann F, Henderson RD, Morrison SC, et al. Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11:194-202.
33. Fitting J-W, Paillex R, Hirt L, et al. Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis. Ann Neurol 1999;46:887-893.
34. National Library of Medicine. Cytokinetics. Study of safety, tolerability & efficacy of CK-2017357 in amyotrophic lateral sclerosis (ALS). 2000. Available at: http://clinicaltrials.gov/show/ NCT01709149. Accessed March 20, 2014.
35. Lyall RA, Donaldson N, Polkey MI, et al. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001;124:2000-2013.
36. Swash M. Why are upper motor neuron signs difficult to elicit in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry 2012;83:659-662.
37. Wohlfart G. Collateral regeneration in partially denervated muscles. Neurology 1958;8:175-180.
38. Krarup C. Lower motor neuron involvement examined by quantitative electromyography in amyotrophic lateral sclerosis. Clin Neurophysiol 2011;122:414-422.
39. Center for Drug Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services. Guidance for industry and FDA staff: qualification process for drug development tools. 2014. Available at: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM230597.pdf. Accessed July 29 2014.
40. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 2004;1:189-195.
41. Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 2009;8:94-109.
42. Simon NG, Ayer G, Lomen-Hoerth C. Is IVIg therapy warranted in progressive lower motor neuron syndromes without conduction block? Neurology 2013;81:2116-2120.
43. Cornblath DR, Kuncl RW, Mellits ED, et al. Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve 1992;15:1111-1115.
44. de Carvalho M, Swash M. Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve 2000;23:344-352.
45. Cheah BC, Vucic S, Krishnan AV, et al. Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models. Amyotroph Lateral Scler 2011;12:33-38.
46. Felice KJ. A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis. Muscle Nerve 1997;20:179-185.
47. McComas AJ, Fawcett PR, Campbell MJ, Sica RE. Electrophysiological estimation of the number of motor units within a human muscle. J Neurol Neurosurg Psychiatry 1971;34:121-131.
48. Kadrie HA, Yates SK, Milner-Brown HS, Brown WF. Multiple point electrical stimulation of ulnar and median nerves. J Neurol Neurosurg Psychiatry 1976;39:973-985.
49. Winhammar JMC, Rowe DB, Henderson RD, Kiernan MC. Assessment of disease progression in motor neuron disease. Lancet Neurol 2005;4:229-238.
50. Ridall PG, Pettitt AN, Henderson RD, McCombe PA. Motor unit number estimation-a Bayesian approach. Biometrics 2006;62:1235-1250.
51. Nandedkar SD, Nandedkar DS, Barkhaus PE, Stalberg EV. Motor unit number index (MUNIX). IEEE Trans Biomed Eng 2004;51: 2209-2211.
52. Boe SG, Stashuk DW, Doherty TJ. Motor unit number estimation by decomposition-enhanced spike-triggered averaging: control data, test-retest reliability, and contractile level effects. Muscle Nerve 2004;29:693-699.
53. Shefner JM, Watson ML, Simionescu L, et al. Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology 2011;77:235-241.
54. Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology 2004;63:1656-1661.
55. Jillapalli D, Shefner JM. Single motor unit variability with threshold stimulation in patients with amyotrophic lateral sclerosis and normal subjects. Muscle Nerve 2004;30:578-584.
56. Vucic S, Kiernan MC. Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol 2006;117:1458-1466.
57. Cheah BC, Lin CS, Park SB, et al. Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clin Neurophysiol 2012;123:2460-2467.
58. Kanai K, Shibuya K, Sato Y, et al. Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2012;83:734-738.
59. Rutkove SB, Aaron R, Shiffman CA. Localized bioimpedance analysis in the evaluation of neuromuscular disease. Muscle Nerve 2002;25:390-397.
60. Rutkove SB, Zhang H, Schoenfeld DA, et al. Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials. Clin Neurophysiol 2007;118:2413-2418.
61. Arts IM, Overeem S, Pillen S, et al. Muscle ultrasonography: a diagnostic tool for amyotrophic lateral sclerosis. Clin Neurophysiol 2012;123:1662-1667.
62. Arts IM, Overeem S, Pillen S, et al. Muscle changes in amyotrophic lateral sclerosis: a longitudinal ultrasonography study. Clin Neurophysiol 2011;122:623-628.
63. Zaidman CM, Wu JS, Wilder S, et al. Minimal training is required to reliably perform quantitative ultrasound of muscle. Muscle Nerve 2014;50:124-128.
64. Turner MR, Agosta F, Bede P, et al. Neuroimaging in amyotrophic lateral sclerosis. Biomark Med 2012;6:319-337.
65. Bede P, Bokde AL, Byrne S, et al. Spinal cord markers in ALS: diagnostic and biomarker considerations. Amyotroph Lateral Scler 2012;13:407-415.
66. Cohen-Adad J, El Mendili MM, Morizot-Koutlidis R, et al. Involvement of spinal sensory pathway in ALS and specificity of cord atrophy to lower motor neuron degeneration. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:30-38.
67. Turner MR, Grosskreutz J, Kassubek J, et al. Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol 2011;10:400-403.
68. Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 2008;131:1540-1550.
69. Vucic S, Kiernan MC. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain 2006;129:2436-2446.
70. Vucic S, Lin CS, Cheah BC, et al. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain 2013;136:1361-1370.
71. Brettschneider J, Petzold A, Sussmuth SD, et al. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006;66:852-856.
72. Puentes F, Topping J, Kuhle J, et al. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2014;85:274-278.
73. Lu C-H, Petzold A, Topping J, et al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry 2014 Jul 9. doi: 10.1136/jnnp-2014-307672.
74. Steinacker P, Hendrich C, Sperfeld AD, et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol 2008;65:1481-1487.
75. Sussmuth SD, Sperfeld AD, Hinz A, et al. CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology 2010; 74:982-987.
76. Blasco H, Corcia P, Moreau C, et al. 1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PloS One 2010;5:e13223.
77. Mitchell RM, Simmons Z, Beard JL, et al. Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve 2010;42:95-103.
78. Mitchell RM, Freeman WM, Randazzo WT, et al. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 2009;72:14-19.
79. Su XW, Simmons Z, Mitchell RM, et al. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis. JAMA Neurol 2013;70:1505-1511.
80. Ganesalingam J, Stahl D, Wijesekera L, et al. Latent cluster analysis of ALS phenotypes identifies prognostically differing groups. PLoS One 2009;4:e7107.
81. Bruijn L, Cudkowicz M, The ALSCTWG. Opportunities for improving therapy development in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:169-173.
82. Sabatelli M, Zollino M, Luigetti M, et al. Uncovering amyotrophic lateral sclerosis phenotypes: clinical features and long-term follow- up of upper motor neuron-dominant ALS. Amyotroph Lateral Scler 2011;12:278-282.
83. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995;118:707-719.
84. Georgoulopoulou E, Fini N, Vinceti M, et al. The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: a population based study in Modena, Italy. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:338-345.
85. Scotton WJ, Scott KM, Moore DH, et al. Prognostic categories for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012;13: 502-508.
86. Chio A, Mora G, Leone M, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 2002;59:99-103.
87. Bourke SC, Tomlinson M, Williams TL, et al. Effects of noninvasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006;5:140-147.
88. Hu WT, Shelnutt M, Wilson A, et al. Behavior matters-cognitive predictors of survival in amyotrophic lateral sclerosis. PloS One 2013;8:e57584.
89. Elamin M, Phukan J, Bede P, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology 2011;76:1263-1269.
90. Desport JC, Preux PM, Truong TC, et al. Nutritional status is a prognostic factor for survival in ALS patients. Neurology 1999;53: 1059-1063.
91. Nakamura R, Atsuta N, Watanabe H, et al. Neck weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry 2013;84:1365-1371.
92. Traxinger K, Kelly C, Johnson BA, et al. Prognosis and epidemiology of amyotrophic lateral sclerosis: analysis of a clinic population, 1997-2011. Neurol Clin Pract 2013;3:313-320.
93. Lee CT, Chiu YW, Wang KC, et al. Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan. J Epidemiol 2013;23:35-40.
94. de Jong SW, Huisman MH, Sutedja NA, et al. Smoking, alcohol consumption, and the risk of amyotrophic lateral sclerosis: a population-based study. Am J Epidemiol 2012;176: 233-239.
95. Cudkowicz ME, McKenna-Yasek D, Sapp PE, et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 1997;41:210-221.
96. Landers JE, Melki J, Meininger V, et al. Reduced expression of the kinesin-associated protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Nat Acad Sci U S A 2009;106:9004-9009.
97. Van Hoecke A, Schoonaert L, Lemmens R, et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med 2012;18:1418-1422.
98. Juneja T, Pericak-Vance MA, Laing NG, et al. Prognosis in familial amyotrophic lateral sclerosis: progression and survival in patients with glu100gly and ala4val mutations in Cu,Zn superoxide dismutase. Neurology 1997;48:55-57.
99. Baumer D, Hilton D, Paine SM, et al. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology 2010;75:611-618.
100. Pinto A, de Carvalho M, Evangelista T, et al. Nocturnal pulse oximetry: a new approach to establish the appropriate time for non-invasive ventilation in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:31-35.
101. Spataro R, Ficano L, Piccoli F, La Bella V. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: effect on survival. J Neurol Sci 2011;304:44-48.
102. Dal Bello-Haas V, Florence JM. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev 2013;5:CD005229.
103. Traynor BJ, Alexander M, Corr B, et al. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry 2003;74:1258-1261.
104. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003;61:456-464.
105. Chang JL, Lomen-Hoerth C, Murphy J, et al. A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/ FTLD. Neurology 2005;65:75-80.
106. Kassubek J, Unrath A, Huppertz HJ, et al. Global brain atrophy and corticospinal tract alterations in ALS, as investigated by voxel-based morphometry of 3-D MRI. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6:213-220.
107. Senda J, Kato S, Kaga T, et al. Progressive and widespread brain damage in ALS: MRI voxel-based morphometry and diffusion tensor imaging study. Amyotroph Lateral Scler 2011;12:59-69.
108. Verstraete E, Veldink JH, Hendrikse J, et al. Structural MRI reveals cortical thinning in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2012;83:383-388.
109. Kwan JY, Meoded A, Danielian LE, et al. Structural imaging differences and longitudinal changes in primary lateral sclerosis and amyotrophic lateral sclerosis. Neuroimage Clin 2012;2:151-160.
110. Filippini N, MacIntosh BJ, Hough MG, et al. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci U S A 2009;106:7209-7214.
111. Agosta F, Pagani E, Petrolini M, et al. Assessment of white matter tract damage in patients with amyotrophic lateral sclerosis: a diffusion tensor MR imaging tractography study. AJNR Am J Neuroradiol 2010;31:1457-1461.
112. van der Graaff MM, Sage CA, Caan MW, et al. Upper and extramotoneuron involvement in early motoneuron disease: a diffusion tensor imaging study. Brain 2011;134:1211-1228.
113. Agosta F, Rocca MA, Valsasina P, et al. A longitudinal diffusion tensor MRI study of the cervical cord and brain in amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry 2009;80:53-55.
114. Valsasina P, Agosta F, Benedetti B, et al. Diffusion anisotropy of the cervical cord is strictly associated with disability in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2007;78:480-484.
115. Stagg CJ, Knight S, Talbot K, et al. Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS. Neurology 2013;80:610-615.
116. Pohl C, Block W, Karitzky J, et al. Proton magnetic resonance spectroscopy of the motor cortex in 70 patients with amyotrophic lateral sclerosis. Arch Neurol 2001;58:729-735.
117. Turner MR, Cagnin A, Turkheimer FE, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [(11)C](R)-PK11195 positron emission tomography study. Neurobiol Dis 2004;15:601-609.
118. Corcia P, Tauber C, Vercoullie J, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One 2012;7:e52941.
119. Turner MR, Hammers A, Al-Chalabi A, et al. Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET. Brain 2005;128:1323-1329.
120. Turner MR, Rabiner EA, Hammers A, et al. [11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain 2005;128:896-905.